Mукосолван Макс (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Mукосолван Макс, is a mucolytic presented as an oral dosage form for oral use. It helps clear excessive mucus in acute and chronic bronchitis and other respiratory tract infections characterized by thick secretions. The product is authorized in the European Union and is commonly prescribed to improve airway clearance in patients with excessive sputum production. GNH USA supplies Mукосолван Макс as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Ambroxol is a mucolytic that reduces the viscosity of respiratory secretions in several bronchial conditions. - Acute bronchitis: facilitates sputum clearance, helping relieve cough and improve breathing. - Chronic bronchitis: reduces mucus thickness, supporting long‑term airway patency. - Respiratory tract infections with excessive mucus: aids in the removal of thick secretions, enhancing patient comfort.

Ambroxol is generally well tolerated, but some patients may experience adverse reactions. Common Side Effects: - Nausea: mild stomach upset that may occur after oral administration. - Vomiting: occasional expulsion of stomach contents. - Taste disturbance: a temporary alteration in taste perception. - Diarrhea: loose stools that usually resolve without treatment. Serious or Rare Side Effects: - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity. - Angioedema: rapid swelling of face, lips, or tongue requiring immediate medical attention. - Anaphylaxis: severe, life‑threatening systemic reaction with difficulty breathing and hypotension.

When using Ambroxol, certain precautions should be observed to ensure safe and effective therapy. - Pediatric use: dosage and duration should be determined by a qualified healthcare professional. - Renal impairment: consider dose adjustment or close monitoring in patients with reduced kidney function. - Hepatic impairment: use with caution; monitor liver function tests if therapy is prolonged. - Concomitant antitussives: avoid combining with strong cough suppressants that may hinder mucus clearance. - Pregnancy and lactation: safety has not been established; prescribe only if potential benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Ambroxol may interact with other medicines; awareness of significant interactions helps prevent adverse outcomes. Major Interactions (Avoid): - CYP2D6 substrates with narrow therapeutic index (e.g., codeine, tramadol): ambroxol can inhibit metabolism, increasing plasma levels and risk of toxicity. - Anticholinergic agents: combined use may reduce mucociliary clearance, counteracting ambroxol’s effect. Moderate Interactions (Monitor Closely): - Other mucolytics (e.g., carbocisteine): additive mucolytic effect may increase gastrointestinal discomfort. - Anticoagulants (e.g., warfarin): monitor INR as ambroxol may slightly affect coagulation parameters. - Antibiotics metabolized by CYP2D6 (e.g., metoprolol): observe for altered plasma concentrations.